Ocean Nanotech LLC — Department of Health and Human Services SBIR Phase I: Liver Cancer is the sixth most common cancer and the third leading cause of cancer death w

Description

Liver Cancer is the sixth most common cancer and the third leading cause of cancer death worldwide. Early diagnosis of liver cancer will have a significant impact on survival by implementation of effective tratment strategies. The development of novel biomarkers in serum for liver cancer proteomics will significantly improve noninvasive for early detection of liver cancer. This proposal is to develop magneto-nanosensor assay for multiplexing detection of several biomarkers associated with hepatocellular cancer. Phase I project will demonstrate feasibility of the magneto nanosensor asseay can detect the proposed 7 biomarkers with high sensitivity and selectivity. The initial validation of small cohort samples from 50 patients and 50 controls will provide a cut off value for the 7 biomarkers or some of them that relevant to HCC cancers. These results are foundation for further validation of the biomarkers in phase II project with large cohort samples from patients/controls. The device is compact in size, simple in operation, inexpensive in cost and high throughput and can be used in clinic labon physician office. The magneto nanosensor, biomarkers and multiplex assays developed in this project will also be useful to cardiovascular disease rish stratification and therapy monitoring, infectious disease diagnostics, central nervous disease early diagnosis and numerous other applications.